Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 4175-4177

  Ostrosky Zeichner, Luis ^a   Rex, John H ^a,b   Pfaller, Michael A ^c   Diekema, Daniel J ^c   Alexander, Barbara D ^d   Andes, David ^e   Brown, Steven D ^f   Chaturvedi, Vishnu ^g   Ghannoum, Mahmoud A ^h   Knapp, Cindy C ⁱ   Sheehan, Daniel J ^j   Walsh, Thomas J ^k  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF IOWA   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f CLINICAL MICROBIOLOGY INSTITUTE   (United States)

^g NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ Trek Diagnostic Systems   (United States)

^j PFIZER INC   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ARTICLE; CANDIDA; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; VALIDITY;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DATABASES, FACTUAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 55849129235     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00420-08     Document Type: Article

References (17)

1. Burgess, D. S., R. W. Hastings, K. K. Summers, T. C. Hardin, and M. G. Rinaldi. 2000. Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans. Diagn. Microbiol. Infect. Dis. 36:13-18.
2. Chen, H., K. J. Suda, R. S. Turpin, M. P. Pai, D. T. Bearden, and K. W. Garey. 2007. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Curr. Med. Res. Opin. 23:1057-1065.
3. CLSI. 2007. Development of in vitro susceptibility testing criteria and quality control parameters; approved standard, 3rd ed. CLSI document M23-A3. CLSI, Wayne, PA.
4. Cuenca-Estrella, M., W. Lee-Yang, M. A. Ciblak, B. A. Arthington-Skaggs, E. Mellado, D. W. Warnock, and J. L. Rodriguez-Tudela. 2002. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob. Agents Chemother. 46:3644-3647.
5. Espinel-Ingroff, A., M. Pfaller, S. A. Messer, C. C. Knapp, N. Holliday, and S. B. Killian. 2004. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Clin. Microbiol. 42:718-721.
6. Espinel-Ingroff, A., M. Pfaller, S. A. Messer, C. C. Knapp, S. Killian, H. A. Norris, and M. A. Ghannoum. 1999. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. J. Clin. Microbiol. 37:591-595.
7. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
8. Klepser, M. E., E. J. Wolfe, R. N. Jones, C. H. Nightingale, and M. A. Pfaller. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395.
9. Matar, M. J., L. Ostrosky-Zeichner, V. L. Paetznick, J. R. Rodriguez, E. Chen, and J. H. Rex. 2003. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob. Agents Chemother. 47:1647-1651.
10. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645.
11. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd ed. CLSI document M27-A2. NCCLS, Wayne, PA.
12. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
13. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.
14. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, A. L. Barry, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
15. Rodriguez-Tudela, J. L., B. Almirante, D. Rodriguez-Pardo, F. Laguna, J. P. Donnelly, J. W. Mouton, A. Pahissa, and M. Cuenca-Estrella. 2007. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob. Agents Chemother. 51:3599-3604.
16. Rodriguez-Tudela, J. L., J. P. Donnelly, M. A. Pfaller, E. Chryssantou, P. Warn, D. W. Denning, A. Espinel-Ingroff, F. Barchiesi, and M. Cuenca-Estrella. 2007. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J. Clin. Microbiol. 45:109-111.
17. Wilson, A. G., S. T. Micek, and D. J. Ritchie. 2005. A retrospective evaluation of fluconazole for the treatment of Candida glabrata fungemia. Clin. Ther. 27:1228-1237.